

SENTARA COMMUNITY PLAN (MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Continuous Glucose Monitors (CGM)

Device Requested: (Check below the CGM that applies, only **ONE** prior authorization form is required)

Formulary Preferred CGMs	
<input type="checkbox"/> FreeStyle Libre 14 Day System (Reader/Sensors)	<input type="checkbox"/> FreeStyle Libre 2 System (Reader/Sensors/Plus Sensors)
<input type="checkbox"/> Dexcom G6™ System (Receiver/Transmitter/Sensors)	<input type="checkbox"/> FreeStyle Libre 3 System (Reader/Sensors/Plus Sensors)
<input type="checkbox"/> Dexcom G7™ System (Receiver/Transmitter/Sensors)	
Non-Formulary – Provider please note: Medical Exception is required for all Non-Formulary CGM requests via submission of the following form: <u>Pharmacy Medical Necessity Request Form</u>	
<input type="checkbox"/> Eversense® (Sensor/Transmitter)	<input type="checkbox"/> Guardian™ 3 (Transmitter/Sensors)
<input type="checkbox"/> Guardian™ 4 (Transmitter/Sensors)	

PROVIDER PLEASE NOTE:

- Only one prior authorization form is required to be submitted for the request of any formulary or non-formulary CGM. If approved, an authorization will be entered for corresponding CGM supplies (e.g., readers, sensors, transmitters).**

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

NPI #: _____

(Continued on next page)

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy:** _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

Quantity Limits:

<u>Dexcom</u>	<u>Freestyle</u>
<ul style="list-style-type: none">• 1 receiver per lifetime• 3 sensors per 30 days• 1 transmitter per 90 days	<ul style="list-style-type: none">• 1 reader kit per lifetime• 2 sensors per 28 days• 2 plus sensors per 30 days

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

☐ Continuous Glucose Monitors – Long Term Use

Length of Authorization: 12 months (1 year)

- ☐ Has the member been approved for a CGM device previously through the Sentara Health Plans medical department? ☐ Yes ☐ No
- ☐ Member requires **long-term** CGM device indicated by **ALL** the following:
 - ☐ Diagnosis of **ONE** of the following:
 - ☐ Type 1 Diabetes Mellitus
 - ☐ Type 2 Diabetes Mellitus
 - ☐ Gestational Diabetes
 - ☐ Member requires a demanding insulin regimen of at least three or more insulin injections per day or current use of an insulin pump
 - ☐ Member or guardian frequently monitors blood glucose levels daily.
 - ☐ Provider attests that the member is motivated and knowledgeable about use of CGMs, is adherent to diabetic treatment plan, and participates in ongoing education and support

(Continued on next page)

❑ Continuous Glucose Monitors – Short Term Use

Length of Authorization: 1 month (30 days)

- ❑ Member requires **short-term** CGM device indicated by **ALL** the following:
 - ❑ Diagnosis of **ONE** of the following:
 - ❑ Type 1 Diabetes Mellitus
 - ❑ Type 2 Diabetes Mellitus
 - ❑ Gestational Diabetes
 - ❑ Member must demonstrate at least **ONE** of the following:
 - ❑ Observed increase in blood glucose levels that takes place in the early morning (also known as The Dawn Phenomenon), known or suspected
 - ❑ Hypoglycemia unawareness (i.e., member does not have symptoms with hypoglycemia)
 - ❑ Nocturnal hypoglycemia, known or suspected
 - ❑ Postprandial hyperglycemia, known or suspected
 - ❑ Significant change to diabetes treatment regimen (e.g., initiation of insulin, change from multiple- dose insulin to insulin pump therapy)
 - ❑ Unexplained hyperglycemia
- ❑ Member requires short term blood glucose monitoring (i.e., 7-14 days)

❑ Replacement Device

- ❑ Member has been previously approved for a CGM
- ❑ Member has been benefiting from the use of the CGM
- ❑ At least **ONE** of the following problems have occurred which limits the use of the member's current CGM:
 - ❑ Reagent or instrument failure/defective devices
 - ❑ Defects in product design
 - ❑ Product instability
 - ❑ Failure to perform according to performance characterized in package insert
 - ❑ Incorrect test results (falsely elevated or decreased glucose results) that cause or contributed to an incorrect patient diagnosis and/or treatment
 - ❑ Unexplained quality control (QC) failures
 - ❑ Any other device problems that may compromise patient health or safety
- ❑ Provider or member must submit documentation that the member's current CGM is not under warranty, including the date of warranty expiration

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****